{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:12:46Z","timestamp":1791313966348,"version":"4.3.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.schres.2022.01.049","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T12:59:34Z","timestamp":1643979574000},"page":"174-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Association between C-reactive protein levels and antipsychotic treatment during 12\u00a0months follow-up period after acute psychosis"],"prefix":"10.1016","volume":"241","author":[{"given":"Farivar","family":"Fathian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Gjestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune A.","family":"Kroken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig Kl\u00e6bo","family":"Reitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Wolfgang","family":"Fleichhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rettenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor K.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Joa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Antonsen","family":"Stabell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Kjelby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igne","family":"Sinkevicute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Alisauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidar M.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.schres.2022.01.049_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2022.01.049_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.schres.2022.01.049_bb0015","series-title":"Correlations between Body Mass Index","author":"Boozalis","year":"2018"},{"key":"10.1016\/j.schres.2022.01.049_bb0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fpubh.2017.00360","article-title":"C-reactive protein correlates with negative symptoms in patients with schizophrenia","volume":"5","author":"Boozalis","year":"2017","journal-title":"Front. Public Health"},{"issue":"5","key":"10.1016\/j.schres.2022.01.049_bb0025","first-page":"1179","article-title":"Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6","volume":"12","author":"Castell","year":"1990"},{"issue":"3","key":"10.1016\/j.schres.2022.01.049_bb0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/obr.12003","article-title":"Obesity and C-reactive protein in various populations: a systematic review and meta-analysis","volume":"14","author":"Choi","year":"2013","journal-title":"Obes. Rev."},{"issue":"7","key":"10.1016\/j.schres.2022.01.049_bb0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.30773\/pi.2017.11.10","article-title":"Decreased IL-1ra and NCAM-1\/CD56 serum levels in unmedicated patients with schizophrenia before and after antipsychotic treatment","volume":"15","author":"Chu","year":"2018","journal-title":"Psychiatry Investig."},{"issue":"2","key":"10.1016\/j.schres.2022.01.049_bb0040","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.drugalcdep.2013.08.027","article-title":"C-reactive protein and substance use disorders in adolescence and early adulthood: a prospective analysis","volume":"133","author":"Costello","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.schres.2022.01.049_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","article-title":"Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment","volume":"154","author":"de Witte","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.01.049_bb0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2007.03.022","article-title":"C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia","volume":"93","author":"Dickerson","year":"2007","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2022.01.049_bb0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2012.10.041","article-title":"C-reactive protein is elevated in schizophrenia","volume":"143","author":"Dickerson","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.01.049_bb0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.psychres.2006.07.011","article-title":"Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia","volume":"149","author":"Fan","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2022.01.049_bb0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jad.2017.09.004","article-title":"High C-reactive protein levels are associated with depressive symptoms in schizophrenia","volume":"225","author":"Faugere","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.schres.2022.01.049_bb0070","series-title":"The IDF consensus worldwide definition of the metabolic syndrome [Internet]","author":"Federation","year":"2020"},{"issue":"6","key":"10.1016\/j.schres.2022.01.049_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00406-017-0847-1","article-title":"Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort","volume":"268","author":"Fond","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.schres.2022.01.049_bb0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.imlet.2013.07.001","article-title":"Serum markers of inflammation and oxidative stress in chronic opium (Taryak) smokers","volume":"153","author":"Ghazavi","year":"2013","journal-title":"Immunol. Lett."},{"issue":"5","key":"10.1016\/j.schres.2022.01.049_bb0090","first-page":"409","article-title":"Impact of smoking on inflammation: overview of molecular mechanisms","volume":"60","author":"Gon\u00e7alves","year":"2011"},{"key":"10.1016\/j.schres.2022.01.049_bb0095","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.psychres.2018.08.042","article-title":"Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia","volume":"269","author":"Gonzalez-Blanco","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2022.01.049_bb0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neubiorev.2017.01.029","article-title":"Altered reward anticipation: potential explanation for weight gain in schizophrenia?","volume":"75","author":"Grimm","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.schres.2022.01.049_bb0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/08039488.2018.1441438","article-title":"Elevated levels of C-reactive protein and IL-6 among the antipsychotic medicating schizophrenia patients of Siliguri, West BengalIndia","volume":"72","author":"Gurung","year":"2018","journal-title":"Nordic journal of psychiatry"},{"key":"10.1016\/j.schres.2022.01.049_bb0110","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2022.01.049_bb0115","series-title":"An introduction to multilevel modeling techniques: MLM and SEM approaches using Mplus","first-page":"67","author":"Heck","year":"2015"},{"issue":"2","key":"10.1016\/j.schres.2022.01.049_bb0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e31819a8dbe","article-title":"Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients","volume":"29","author":"Henderson","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2022.01.049_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2632","article-title":"C-reactive protein levels and treatment resistance in schizophrenia-a danish population-based cohort study","volume":"32","author":"Horsdal","year":"2017","journal-title":"Human Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2022.01.049_bb0130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.biopsych.2013.06.010","article-title":"Immune system disturbances in schizophrenia","volume":"75","author":"Horvath","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"22","key":"10.1016\/j.schres.2022.01.049_bb0135","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.2174\/138161209788957528","article-title":"Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging","volume":"15","author":"Howes","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2022.01.049_bb0140","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.3389\/fimmu.2018.02230","article-title":"C-reactive protein: higher during acute psychotic episodes and related to cortical thickness in schizophrenia and healthy controls","volume":"9","author":"Jacomb","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.schres.2022.01.049_bb0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12888-016-0769-x","article-title":"The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis","volume":"16","author":"Johnsen","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2022.01.049_bb0150","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S2215-0366(20)30341-2","article-title":"Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial","volume":"7","author":"Johnsen","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2022.01.049_bb0155","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.schres.2015.08.019","article-title":"Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups","volume":"168","author":"Joseph","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2022.01.049_bb0160","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.schres.2018.06.039","article-title":"Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naive first episode psychosis individuals: a 3months randomized study","volume":"202","author":"Juncal-Ruiz","year":"2018","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2022.01.049_bb0165","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2022.01.049_bb0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2022.01.049_bb0175","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.psychres.2018.10.022","article-title":"Low-grade inflammation in first-episode psychosis is determined by increased waist circumference","volume":"270","author":"Keinanen","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2022.01.049_bb0180","series-title":"Principles and Practice of StructuralEquation Modeling","author":"Kline","year":"2016"},{"issue":"3","key":"10.1016\/j.schres.2022.01.049_bb0185","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2022.01.049_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fpsyt.2014.00011","article-title":"A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation","volume":"5","author":"Kroken","year":"2014","journal-title":"Frontiers in psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2022.01.049_bb0195","doi-asserted-by":"crossref","first-page":"166.e117","DOI":"10.1016\/j.amjmed.2005.06.057","article-title":"What does minor elevation of C-reactive protein signify?","volume":"119","author":"Kushner","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.schres.2022.01.049_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2022.01.049_bb0205","doi-asserted-by":"crossref","first-page":"9541459","DOI":"10.1155\/2018\/9541459","article-title":"Haloperidol abrogates matrix Metalloproteinase-9 expression by inhibition of NF-kappaB activation in stimulated human monocytic cells","volume":"2018","author":"Lee","year":"2018","journal-title":"Mediat. Inflamm."},{"issue":"2","key":"10.1016\/j.schres.2022.01.049_bb0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clim.2005.08.004","article-title":"C-reactive protein: ligands, receptors and role in inflammation","volume":"117","author":"Marnell","year":"2005","journal-title":"Clinical immunology (Orlando, Fla.)"},{"issue":"11","key":"10.1016\/j.schres.2022.01.049_bb0215","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2022.01.049_bb0220","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2022.01.049_bb0225","series-title":"Toolkit for Evaluating Substance Abuse in Persons With Severe Mental Illness","author":"Mueser","year":"1995"},{"key":"10.1016\/j.schres.2022.01.049_bb0230","series-title":"Mplus Version 8","author":"Muth\u00e9n","year":"2017"},{"key":"10.1016\/j.schres.2022.01.049_bb0235","series-title":"C Reactive Protein (CRP)","author":"Nehring","year":"2019"},{"key":"10.1016\/j.schres.2022.01.049_bb0240","series-title":"Longitudinal Structural Equation Modeling: A Comprehensive Introduction","author":"Newsom","year":"2015"},{"key":"10.1016\/j.schres.2022.01.049_bb0245","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.psychres.2017.12.025","article-title":"Joint evaluation of serum C-reactive protein levels and polygenic risk scores as risk factors for schizophrenia","volume":"261","author":"Nimgaonkar","year":"2018","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.schres.2022.01.049_bb0250","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/1570159X16666180119144538","article-title":"Protein-C reactive as biomarker predictor of schizophrenia phases of Illness?","volume":"16","author":"Orsolini","year":"2018","journal-title":"A Systematic Review. Current neuropharmacology"},{"issue":"3","key":"10.1016\/j.schres.2022.01.049_bb0255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.schres.2022.01.049_bb0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2022.01.049_bb0265","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ng.2742","article-title":"Genome-wide association analysis identifies 13 new risk loci for schizophrenia","volume":"45","author":"Ripke","year":"2013","journal-title":"Nature Genetics"},{"issue":"9","key":"10.1016\/j.schres.2022.01.049_bb0270","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ijnp\/pyy062","article-title":"Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis","volume":"21","author":"Romeo","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2-3","key":"10.1016\/j.schres.2022.01.049_bb6000","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"issue":"7510","key":"10.1016\/j.schres.2022.01.049_bb0275","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"<collab>Schizophrenia Working Group of the Psychiatric Genomics","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.schres.2022.01.049_bb0280","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharep.2014.09.007","article-title":"Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity","volume":"67","author":"Sobis","year":"2015","journal-title":"Pharmacological reports : PR"},{"issue":"7256","key":"10.1016\/j.schres.2022.01.049_bb0285","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","article-title":"Common variants conferring risk of schizophrenia","volume":"460","author":"Stefansson","year":"2009","journal-title":"Nature"},{"issue":"1-3","key":"10.1016\/j.schres.2022.01.049_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \"just the facts\" 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.schres.2022.01.049_bb0295","article-title":"The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study","volume":"12","author":"Tibuakuu","year":"2017"},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.01.049_bb0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","article-title":"Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis","volume":"151","author":"Tourjman","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.01.049_bb0305","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2022.01.049_bb0310","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3810\/pgm.2011.01.2252","article-title":"C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians","volume":"123","author":"Windgassen","year":"2011","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.schres.2022.01.049_bb0315","series-title":"International Statistical Classification of Diseases and Related Health Problems","year":"2007"},{"key":"10.1016\/j.schres.2022.01.049_bb0320","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.schres.2018.05.017","article-title":"Changes in metabolism and microbiota after 24-week risperidone treatment in drug naive, normal weight patients with first episode schizophrenia","volume":"201","author":"Yuan","year":"2018","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:47:06Z","timestamp":1760298426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996422000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":64,"alternative-id":["S0920996422000597"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2022.01.049","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between C-reactive protein levels and antipsychotic treatment during 12\u00a0months follow-up period after acute psychosis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2022.01.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}